Cavagna Lorenzo, Scorletti Eva, Romano Mariaeva, Cagnotto Giovanni, Caporali Roberto
G Ital Nefrol. 2013 Jul-Aug;30(4).
Systemic lupus erythematosus (SLE) is an autoimmune condition with a wide range of manifestations. Among the various targets of the disease, the kidney holds a very important place. In fact, renal involvement is one of the most important and frequent features of the disease, deeply affecting a patient's prognosis and influencing the therapeutic approach. In the last few years, some progress has been achieved in terms of both disease classification and treatment. In 2012, the Systemic Lupus International Collaborating Clinics (SLICC) published the new classification criteria for SLE and the American College of Rheumatology established recommendations for the screening, treatment, and management of SLE nephritis. These new points of view derived from the recent evolution of medical knowledge, technology, and practice in the field of SLE in general, and lupus nephritis in particular. Moreover, it is important to remember that SLE still remains a systemic disorder and that a multi-disciplinary approach is the optimal way to manage these patients.
系统性红斑狼疮（SLE）是一种具有广泛临床表现的自身免疫性疾病。在该疾病的各种靶器官中，肾脏占据着非常重要的位置。事实上，肾脏受累是该疾病最重要且最常见的特征之一，深刻影响患者的预后并影响治疗方法。在过去几年中，在疾病分类和治疗方面都取得了一些进展。2012年，系统性红斑狼疮国际协作临床中心（SLICC）发布了SLE的新分类标准，美国风湿病学会也制定了SLE肾炎筛查、治疗和管理的建议。这些新观点源于SLE领域，尤其是狼疮性肾炎领域医学知识、技术和实践的最新发展。此外，必须记住SLE仍然是一种全身性疾病，多学科方法是管理这些患者的最佳方式。
